Rahul Dev Jayant, assistant professor in the Department of Immunology, has received a $25,000 grant from The Campbell Foundation in Ft. Lauderdale to continue his research on sustained-release nanoformulation to deliver antiretroviral (ARV) medication for patients living with HIV/AIDS.
Using FIU patented nanotechnology, Jayant, a researcher at the Herbert Wertheim College of Medicine’s Center for Personalized Nanomedicine, has successfully integrated Tenofovir, an antiretroviral drug used to fight HIV, into a long-active nanoformulation that can release the medication for up to one week.
“Now, with the generous help from The Campbell Foundation, we will be working toward the development of single-dose formulation that can release the ARV drugs up to one month,” Jayant said.
Sustained release of antiretroviral medication has the potential to be a game changer for many people living with HIV/AIDS who may have trouble adhering to the daily pill dosing that current treatments require.
The Campbell Foundation has been funding cutting-edge research into a cure for HIV since its creation in 1995 by the late Richard Campbell Zahn, the chemist who developed Herpecin-L Lip Balm for the treatment of cold sores and fever blisters.
“These fast-track grants to South Florida-based researchers show our Board of Directors’ ongoing commitment to addressing HIV/AIDS right here in our own backyard,” said Campbell Foundation Trustee Bill Venuti.
Story originally published on FIU News: news.fiu.edu/2017/06/researcher-awarded-grant-for-sustained-release-hivaids-drug-study/112521